Home » Stocks » RNAZ

TransCode Therapeutics, Inc. (RNAZ)

TransCode Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $8.00 - $10.00
Current IPO price range
Market Cap 76.37M
Revenue (ttm) n/a
Net Income (ttm) -2.34M
Shares Out 8.49M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News

Transcode Therapeutics, a preclinical biotech developing RNA-based therapies for cancer, filed on Friday with the SEC to raise up to $30 million in an initial public offering.

1 month ago - NASDAQ

TransCode Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About RNAZ

TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. Our strategy seeks to overcome RNA-based therapeutics delivery challenges by repurposing a particle used extensively in humans for imaging purposes to deliver synthetic RNA molecules (called oligonucleotides) to cancer cells. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving pat... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Pending
CEO
R. Michael Dudley
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
RNAZ
Full Company Profile

Financial Performance

Financial Statements